Search | Clinical Trials Finder

Conditions: Acute Hypoxemic Respiratory Failure
Interventions: L-Citrulline, Placebo; Drug
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: End Stage Renal Disease
Interventions: nutritional supplement, recombinant human growth hormone (rcGH), exercise; Dietary Supplement · Drug · Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hepatocellular Carcinoma
Interventions: ThermoDox, 5% Dextrose Solution; Drug
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older
Enrollment: 701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 9
States / cities: Los Angeles, California • Jacksonville, Florida • Louisville, Kentucky + 6 more

Conditions: Solid Tumours
Interventions: SB-715992, carboplatin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Major Advanced Solid Tumors Other Than Colorectal
Interventions: PM01183; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Aurora, Colorado • Chicago, Illinois

Conditions: Tolerability, Healthy, Elderly
Interventions: AZD9742, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 65 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: Up to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Mitral Regurgitation
Interventions: Mydfrin; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Angina, Unstable, Cardiovascular Diseases, Heart Diseases, Coronary Disease, Myocardial Infarction, Heart Failure, Congestive
Interventions: GIK, Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 30 Years and older
Enrollment: 911 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 13
States / cities: Anchorage, Alaska • New Haven, Connecticut • Macon, Georgia + 10 more

Conditions: Neuroendocrine Tumors
Interventions: 177Lu-DOTA-EB-TATE, Amino Acid Solution; Drug · Other
Lead sponsor: Molecular Targeting Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies, Anemia
Interventions: Alemtuzumab, Total Body Irradiation, Melphalan, Busulfan, Phenytoin, Fludarabine, Cyclophosphamide, Horse Antithymocyte Globulin, Rabbit Antithymocyte Globulin, Thiotepa; Drug · Radiation
Lead sponsor: Columbia University; Other
Eligibility: Up to 30 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis
Interventions: Intravenous Acetaminophen (room temperature), Intravenous Vitamin C (refrigerated), 5% Dextrose (room temperature), 5% Dextrose refrigerated; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more

Conditions: Colon Cancer Liver Metastasis
Interventions: Lyso-Thermosensitive Liposomal Doxorubicin, 5% Dextrose Solution, ThermoDox; Drug · Other
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • The Bronx, New York • Cleveland, Ohio + 1 more

Conditions: Obesity, Healthy
Interventions: PET Scan, Mixed Meal Test, Muscle sympathetic nerve activity (MSNA), Oral Glucose Tolerance Test, Body Composition, Percent Body Fat & Percent Body Water (Tanita scale), CT Scan, Body Composition, Percent Body Fat & Percent Body Water (DXA Scan); Diagnostic Test · Dietary Supplement · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Ehlers-Danlos Syndrome, Low Back Pain, Sacroiliac Instability
Interventions: Dextrose 50% Intravenous Solution, Lidocaine 1% Injectable Solution; Drug
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Cervical Cancer
Interventions: Pembrolizumab, Paclitaxel, Cisplatin, Carboplatin, Bevacizumab, Placebo to pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 20
States / cities: Anchorage, Alaska • Phoenix, Arizona • Orange, California + 15 more

Conditions: Diabetes, Hypoglycemia
Interventions: hyperinsulinemic-hypoglycemic clamp, 13C-MRS procedure/Acetate infusion; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions: Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST); Drug · Diagnostic Test
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Lysosomal Diseases, Gangliosidosis, GM1
Interventions: AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam; Biological · Procedure · Drug + 3 more
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 6 Months to 12 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Neoplasms
Interventions: pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more

Conditions: Macular Degeneration, Choroidal Neovascularization
Interventions: Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 36
States / cities: Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more

Search by objective public record fields.

Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19

Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients

Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)

Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Use of Phenylephrine for Assessment of Mitral Regurgitation Severity

IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)

Sympathetic Activation in Obesity

The Ultrasound-Guided Dextrose Prolotherapy in Ehlers-Danlos Syndrome Patients

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation

Effect of Insulin Lowering on Lipogenesis

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization